Synapse - Ross Firestone

Results (35)

Clinical significance of baseline body mass index and its trajectory during triplet induction therapy in newly diagnosed multiple myeloma

Meeting Abstract

Thirugnanasambandam, R. P.; Firestone, R.; Derkach, A.; Maclachlan, K.; Hultcrantz, M.; Mailankody, S.; Lahoud, O.; Landau, H.; Chung, D.; Shah, G.; more...
Clinical Lymphoma, Myeloma and Leukemia (2023)

Fulltext@MSK | Save

Patterns of cytokine release syndrome with teclistamab in relapsed/refractory multiple myeloma with or without prior T-cell redirection therapy

Meeting Abstract

Hamadeh, I.; Shekarkhand, T.; Rueda, C.; Firestone, R.; Wang, A.; Korde, N.; Hultcrantz, M.; Lesokhin, A.; Mailankody, S.; Hassoun, H.; more...
Clinical Lymphoma, Myeloma and Leukemia (2023)

Fulltext@MSK | Save

Bispecific T-cell engager response is driven by pre-treatment CD8+ effector memory cells and inhibited by TIGIT+ Tregs in relapsed/refractory multiple myeloma

Meeting Abstract

Firestone, R.; McAvoy, D.; Shekarkhand, T.; Serrano, E.; Hamadeh, I.; Wang, A.; Zhu, M.; Patel, D.; Tan, C. R.; Hultcrantz, M.; more...
Clinical Lymphoma, Myeloma and Leukemia (2023)

Fulltext@MSK | Save

An embarrassment of riches: Three FDA-approved bispecific antibodies for relapsed refractory multiple myeloma

Review

Firestone, R.; Lesokhin, A. M.; Usmani, S. Z.
Blood Cancer Discovery (2023)

Fulltext@MSK | Save

Evaluating the efficacy of commercial teclistamab in relapsed refractory multiple myeloma patients with prior exposure to anti-BCMA therapies

Meeting Abstract

Firestone, R.; Shekarkhand, T.; Patel, D.; Tan, C. R. C.; Hultcrantz, M.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; Shah, U. A.; Korde, N.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save